BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Bayer Enrolls First Patient in Global Phase III SOHO-02 Trial Evaluating BAY 2927088 as First-Line Therapy for HER2-Mutant NSCLC

Bayer announced that the first patient has been enrolled in the global Phase III SOHO-02 trial, an open-label, randomized, multicenter clinical trial, asse...

August 30, 2024 | News

Merck Initiates Phase III MyClad Trial Dosing First Patient in Study of Oral Cladribine for Generalized Myasthenia Gravis

Merck, a leading science and technology company, announced the first patient has been dosed in the Phase III MyClad trial (NCT06463587) evaluating the effi...

August 30, 2024 | News

Yunovia Gains MFDS Clearance for Phase 1 MAD Study of Oral GLP-1 Agonist for Diabetes and Obesity

Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has clea...

August 28, 2024 | News

Shilpa Medicare Completes Phase 1 Trial for sRbumin®, India’s First Recombinant Human Albumin

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship prod...

August 28, 2024 | News

Telix Pharmaceuticals Submits NDA to FDA for Innovative Brain Cancer Imaging Agent Pixclara®

Telix Pharmaceuticals announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for ...

August 28, 2024 | News

ArkBio CEO Presents Promising IPF Drug AK3280 at 8th Annual IPF Summit in Boston

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr. Jim Wu, Chief...

August 27, 2024 | News

Fujitsu Launches Major Initiative to Attract Global Clinical Trials to Japan, Tackling the Nation's 'Drug Loss' Issue

Fujitsu announced that it will begin initiatives to attract global clinical trials to Japan and tackle the ‘drug loss’ issue by working w...

August 26, 2024 | News

Mabwell Receives NMPA Approval to Initiate Phase III Study of 9MW2821 in Recurrent or Metastatic Cervical Cancer

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (C...

August 26, 2024 | News

CanariaBio Completes Enrollment for Phase 2 Study of Oregovomab with Chemotherapy in Advanced Ovarian Cancer

CanariaBio Inc, a leading late-stage biotechnology company, announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study ...

August 26, 2024 | News

AiViva Biopharma Completes Enrollment in Phase 1 Trial of AIV007 for Wet AMD and DME

AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 tria...

August 26, 2024 | News

Everest Medicines Launches First Clinical Trial for Personalized mRNA Cancer Vaccine EVM16 in China

Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeut...

August 22, 2024 | News

CARsgen Therapeutics Completes Enrollment in Pivotal Phase II Trial of Satri-Cel for Advanced Gastric Cancer in China

CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...

August 20, 2024 | News

Astellas Pharma Gains NMPA Approval for PADCEV™ in China to Treat Advanced Urothelial Cancer

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that the Center for Drug Evaluation (CDE) of C...

August 20, 2024 | News

Pfizer and BioNTech Announce Mixed Results from Phase 3 Trial of Combination mRNA Vaccine for Influenza and COVID-19

Pfizer Inc. and BioNTech SE announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vac...

August 19, 2024 | News

Stay Connected